Journal of Applied Biological Chemistry

The Korean Society for Applied Biological Chemistry (한국응용생명화학회)
권호 표지
DOI QR코드

DOI QR Code

The anticancer effect of Bioconverted Danggui Liuhuang Decoction EtOH extracts in human colorectal cancer cell lines

  • Park, Hyo-Hyun (Department of Korean Medicine Development, National Development Institute of Korean Medicine) ;
  • Park, Ji-Eun (Department of Korean Medicine Development, National Development Institute of Korean Medicine) ;
  • Son, Eun-Kyung (Department of Korean Medicine Development, National Development Institute of Korean Medicine) ;
  • Kim, Bo-Mi (Department of Korean Medicine Development, National Development Institute of Korean Medicine) ;
  • So, Jai-Hyun (Department of Korean Medicine Development, National Development Institute of Korean Medicine)
  • Received : 2019.12.02
  • Accepted : 2020.03.11
  • Published : 2020.03.31
Download PDF
⟨ Previous Next ⟩

Abstract

Objective: The objective of our study was to investigate anti-cancer effects of Danggui Liuhuang Decoction extract bioconverted by protease liquid coenzyme of Aspergillus kawachii (DLD-BE), compared to a non-bioconverted DLD extract (DLD-E) and determine the underlying mechanisms. Methods: DLD-E and DLD-BE were evaluated for their ability to modulate these signaling pathways and suppress the proliferation of human colorectal cancer (CRC) cells, HCT-116, LoVo, and HT-29. The anti-cancer effects of DLD-E and DLD-BE were measured by using proliferation and migration assays, cell cycle analysis, Western blots, and real-time PCR. Results: In this study, treatment with DLD-E and DLD-BE at concentrations of 25-100 ㎍/mL inhibited proliferation and migration in human CRC cells. DLD-BE induced apoptotic cell death and decreased COX-2 expression in HT-29 cells. The mechanisms of action included modulation of the AKT and extracellular-signal-regulated kinase signaling cascades along with inhibition of COX-2 expression. The results demonstrate novel anti-cancer mechanisms of DLD-BE against the growth of human CRC cells. Thus, we propose that DLD-BE can be developed as a more potent supplement to inhibit colorectal tumor growth and intestinal inflammation than DLD-E.

Keywords

References

  1. Siegel R, Ma J, Zou Z, Jemal A (2014) Cancer statistics, 2014. CA Cancer J Clin 64: 9-29 https://doi.org/10.3322/caac.21208
  2. Siegel R, Desantis C, Jemal A (2014) Colorectal cancer statistics, 2014. CA Cancer J Clin 64: 104-117 https://doi.org/10.3322/caac.21220
  3. Sano H, Kawahito Y, Wilder RL, Hashiramoto A, Mukai S, Asai K, Kimura S, Kato H, Kondo M, Hla T (1995) Expression of cyclooxygenase-1 and -2 in human colorectal cancer. Cancer Res 55: 3785-3789
  4. Eberhart CE, Coffey RJ, Radhika A, Giardiello FM, Ferrenbach S, DuBois RN (1994) Up-regulation of cyclooxygenase 2 gene expression in human colorectal adenomas and adeno carcinomas. Gastroenterology 107: 1183-1188 https://doi.org/10.1016/0016-5085(94)90246-1
  5. Singer II, Kawka DW, Schloemann S, Tessner T, Riehl T, Stenson WF (1998) Cyclooxygenase 2 is induced in colonic epithelial cells in inflammatory bowel disease. Gastroenterology 115: 297-306 https://doi.org/10.1016/S0016-5085(98)70196-9
  6. Hendel J, Nielsen OH (1997) Expression of cyclooxygenase-2 mRNA in active inflammatory bowel disease. Am J Gastroenterol 92: 1170-1173
  7. Eberhart CE, Coffey RJ, Radhika A, Giardiello FM, Ferrenbach S, DuBois RN (1994) Up-regulation of cyclooxygenase-2 gene expression in human colorectal adenomas and adenocarcinomas. Gastroenterology 107: 1183-1188 https://doi.org/10.1016/0016-5085(94)90246-1
  8. Niiro H, Otsuka T, Ogami E, Yamaoka K, Nagano S, Akahoshi M, Nakashima H, Arinobu Y, Izuhara K, Niho Y (1998) MAP kinase pathways as a route for regulatory mechanisms of IL-10 and IL-4 which inhibit COX-2 expression in human monocytes. Biochem Biophys Res Commun 250: 200-205 https://doi.org/10.1006/bbrc.1998.9287
  9. Phillips WA, Clair FS, Munday AD, Thomas RJS, Mitchell CA (1998) Increased levels of phosphatidylinositol 3-kinase activity in colorectal tumors. Cancer 83: 41-47 https://doi.org/10.1002/(SICI)1097-0142(19980701)83:1<41::AID-CNCR6>3.0.CO;2-H
  10. Sasaki T, Ine-Sasaki J, Hone J, Bachmeier K, Fata JE, Li M, Su A. (2000) Colorectal carcinomas in mice lacking the catalytic subunit of PI(3)Kgamma. Nature 406: 897-902 https://doi.org/10.1038/35022585
  11. Mazhar D, Ang R, Wazman J (2006) COX inhibitors and breast cancer. Br J Cancer 94: 346-350 https://doi.org/10.1038/sj.bjc.6602942
  12. Das D, Arber N, Jankowski JA (2007) Chemoprevention of colorectal cancer. Digestion 76: 51-67 https://doi.org/10.1159/000108394
  13. Silverstein FE, Faich G, Goldstein JL, Simon LS, Pincus T, Whelton A, Makuch R, Eisen G, Agrawal NM, Stenson WF, Burr AM, Zhao WW, Kent JD, Lefkowith JB, Verburg KM, Geis GS (2000) Gastrointestinal toxicity with celecoxib vs nonsteroidal anti-inflammatory drugs for osteoarthritis and rheumatoid arthritis: the CLASS study: a randomized controlled trial. Celecoxib Long-term Arthritis Safety Study. J Am Med Am 284: 1247-1255 https://doi.org/10.1001/jama.284.10.1247
  14. Lisse JR, Perlman M, Johansson G, Shoemaker JR, Schechtman J, Skalky CS, Dixon ME, Polis AB, Mollen AJ, Geba GP; ADVANTAGE Study Group (2003) Gastrointestinal tolerability and effectiveness of rofecoxib versus naproxen in the treatment of osteoarthritis: a randomized, controlled trial. Ann Intern Med 139: 539-546 https://doi.org/10.7326/0003-4819-139-7-200310070-00005
  15. Bombardier C, Laine L, Reicin A, Shapiro D, Burgos-Vargas R, Davis B, Day R, Ferraz MB, Hawkey CJ, Hochberg MC, Kvien TK, Schnitzer TJ; VIGOR Study Group (2000) Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis. N Engl J Med 343: 1520-1528 https://doi.org/10.1056/NEJM200011233432103
  16. Hur J (2005; Originally published in 1610) Dongui Bogam. Yeogang Publishing Company, Seoul
  17. Li DY. Lan Shi Mi Cang (2012; Originally published in 1276) China Tianjin Science and Technology Press, Tianjin
  18. Kim DG, Kim KS (2007) Effects of dangkwiyughwangtang and okbyoungpoongsangamibang on the immune response induced by methotrexate in mice. J Korean Orient Pediatr 21: 189-209
  19. Kim SB, Kang OH, Keum JH, Mun SH, Seo YS, Choi JG, Kim MR, Rho JR, Shin DW, Kil KJ, Kwon DY (2012) Anti-inflammatory effects of Danggui Liuhuang Decoction () in RAW 264.7 cells. Chin J Integr Med 1-7 https://doi.org/10.1007/bf02857421
  20. Yang EJ, Kim SI, Park SY, Bang HY, Jeong JH, So JH, Rhee IK, Song KS (2012) Fermentation enhances the in vitro antioxidative effect of onion (Allium Cepa) via an increase in quercetin content. Food Chem Toxicol 50: 2042-2048 https://doi.org/10.1016/j.fct.2012.03.065
  21. Vyas S, Zaganjor E, Haigis MC (2016) Mitochondria and Cancer. Cell 166: 555-566 https://doi.org/10.1016/j.cell.2016.07.002
  22. Del Bufalo D, Biroccio A, Leonetti C, Zupi G (1997) Bcl-2 overexpression enhances the metastatic potential of a human breast cancer line. FASEB J 11: 947-953 https://doi.org/10.1096/fasebj.11.12.9337147
  23. Pinkas J, Martin SS, Leder P (2004) Bcl-2-mediated cell survival promotes metastasis of EpH4 betaMEKDD mammary epithelial cells. Mol Cancer Res 2: 551-556
  24. Halilovic E, She QB, Ye Q, Pagliarini R, Sellers WR, Solit DB, Rosen N (2010) PIK3CA mutation uncouples tumor growth and cyclin D1 regulation from MEK/ERK and mutant KRAS signaling. Cancer Res 70: 6804-6814 https://doi.org/10.1158/0008-5472.CAN-10-0409
  25. Wolter F, Akoglu B, Clausnitzer A, Stein J (2001) Downregulation of the cyclin D1/Cdk4 complex occurs during resveratrol-induced cell cycle arrest in colon cancer cell lines. J Nutr 131: 2197-2203 https://doi.org/10.1093/jn/131.8.2197
  26. Kelloff GJ, Fay JR, Steele VE, Lubet RA, Boone CW, Crowell JA, Sigman CC (1996) Epidermal growth factor receptor tyrosine kinase inhibitors as potential cancer chemopreventives. Cancer Epidemiol Biomarkers Prev 5: 657-666
  27. Wang D, Dubois RN (2008) Peroxisome proliferator-activated receptors and progression of colorectal cancer. Am J Respir Cell Mol Biol 39: 689-696 https://doi.org/10.1165/rcmb.2007-0426OC
  28. Wang D, Dubois RN (2006) Prostaglandins and cancer. Gut 55: 115-122 https://doi.org/10.1136/gut.2004.047100
  29. Robert T, Elizabeth B, Fabio M, Madeine W (2015) Phytochemicals in cancer prevention and management? BJMP 8: a815
  30. Lee SG, Kim JS, Lee HS, Lim YM, So JH, Hahn D, Ha YS, Nam JO (2017) Bioconverted Orostachys japonicas extracts suppress angiogenic activity of Ms-1 endothelial cells. Int J Mol Sci 18: 2615 https://doi.org/10.3390/ijms18122615
  31. Jung TD, Shin GH, Kim JM, Oh JW, Choi SI, Lee JH, Cho ML, Lee SJ, Heo IJ, Park SJ (2016) Changes in Lignan Content and Antioxidant Activity of Fermented Sesame (Sesame indicum L.) by Cultivars. J Korean Soc Food Sci Nutr 45: 143-148 https://doi.org/10.3746/JKFN.2016.45.1.143
  32. Im AR, Song JH, Lee MY, Yeon SH, Um KA, Chae S (2014) Antiwrinkle effects of fermented and non-fermented Cyclopia Intermedia in hairless mice. BMC Complement. Altern Med 14: 424
  33. Gao J1, Liu ZJ, Chen T, Zhao D (2014) Pharmaceutical properties of calycosin, the major bioactive isoflavonoid in the dry root extract of Radix astragali. Pharm Biol. 52(9): 1217-1222 https://doi.org/10.3109/13880209.2013.879188
  34. El-Kott AF, Al-Kahtani MA, Shati AA (2019) Calycosin induces apoptosis in adenocarcinoma HT29 cells by inducing cytotoxic autophagy mediated by SIRT1/AMPK-induced inhibition of Akt/mTOR. Clin Exp Pharmacol Physiol. 46: 944-954 https://doi.org/10.1111/1440-1681.13133
  35. Kim SJ, Kim HJ, Kim HR, Lee SH, Cho SD, Choi CS, Nam JS, Jung JY (2012) Antitumor actions of baicalein and wogonin in HT-29 human colorectal cancer cells. Mol Med Rep. 6: 1443-1449 https://doi.org/10.3892/mmr.2012.1085